Nonsquamous Non-small-cell Lung Cancer
Conditions
Interventions
Pemetrexed and Carboplatin plus Bevacizumab with maintenance pemetrexed as first-line therapy
Sponsors
Kyorin Univercity Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) histologically or cytologically confirmed 2)newly diagnosed stage IIIB,IV 3)recurrent NSCLC for which they had not received chemotherapy 4)measurable or nonmeasurable disease as defined by Response Evaluation Criteria in Solid Tumors 5)ECOG Performance status 0-1 6)age 20-74 years 7)Patients expected to survive longer than at least three months 8)adequate hematologic, hepatic, and renal functions 9)Patients who provide written informed consent
Exclusion criteria
Exclusion criteria: 1)active or symptomatic interstitial lung disease 2)clinically significant cardiovascular disease and DVT 3)medically uncontrolled hypertension and diabetes 4)clinically significant infectious disease 5)history of diverticulitis or clinically significant diverticular disease 6)history of gross hemoptysis (2.5ml) 7)primary tumor in close proximity to a major vessel 8)primary tumor with cavitation 9)melena 10)regular use of aspirin 11)proteinuria(Grade2) 12)history of thrombotic or hemorrhagic disorder 13)uncontrollable pleural effusion and ascites 14)symptomatic brain metastasis 15)active double cancer 16)pregnancy or lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary end point of this study was PFS, defined as the time from registration to the time of documented disease progression. | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety,Response rate,Disease control rate,OS,1-year survival rate,QOL | — |
Countries
Japan
Contacts
Public ContactTakuma Yokoyama
Kyorin Univercity Hospital Department of Respiratory Medicine
Outcome results
None listed